Voss et al. [41] examined patients with metastatic renal cell carcinoma (RCC) of any histologic subtype who had received two to three prior lines of molecularly targeted therapy, including at least one VEGF-inhibiting regimen, while Weiss et al. [43] studied patients with advanced solid tumor malignancies. This evidence concerns the gene VEGFA and renal cell carcinoma.